Butterfly Medical Overview
Butterfly Medical is developing treatment for enlarged prostate (BPH). The Butterfly implant is designed to fit the unique anatomy of the prostatic urethra, dilate the obstructed area, and restore urine flow and quality of life. The delivery procedure takes minutes to complete and is a minimally invasive treatment. The company is conducting a clinical trial, with dozens of patients treated so far and several additional clinical trials pending. So far, the data show that the Butterfly device offers a simple, fast, and safe treatment for men with BPH symptoms.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
/PRNewswire/ -- Butterfly Medical, a medical device company focused on alleviating suffering in patients with BPH (Benign Prostatic Hyperplasia), announced...
Butterfly Medical, a company specializing in medical devices for Benign Prostatic Hyperplasia (BPH), announced the presentation of new research on its prostatic retraction device at the American Urological Associations Annual Conference in April 2025. The device, which has CE Mark Approval, is minimally invasive and currently undergoing a pivotal clinical study in the U.S. It offers a reversible procedure that can be performed under local anesthesia, providing significant relief for patients. The presentations at the conference will highlight the devices long-term effectiveness, with positive outcomes observed up to five years post-treatment.
Product StageFDA approved/pending approval
growth-positive
/PRNewswire/ -- Butterfly Medical, a medical device company focused on alleviating suffering in patients with BPH (Benign Prostatic Hyperplasia), announced...
Butterfly Medical, a company focused on developing a minimally invasive treatment for Benign Prostatic Hyperplasia (BPH), has appointed Dr. James Ulchaker as Chief Medical Officer. Dr. Ulchaker will support the companys efforts toward FDA approval and U.S. commercialization of their novel implantable device, which aims to improve the quality of life for patients with BPH. The device, which has already received CE Mark Approval, is currently undergoing pivotal clinical trials in the U.S. This strategic appointment is expected to enhance Butterfly Medicals medical strategy and patient-focused care, positioning the company for growth as it seeks to address a significant healthcare challenge.
Management ChangesProduct Stage
growth-positive
Treating enlarged prostate without surgery or drugs
Butterfly Medical has developed a metal coil device to treat non-cancerous benign prostatic hyperplasia (BPH) without drugs or surgery. The device can be inserted by a urologist in a quick outpatient procedure and is reversible. Butterfly aims to provide a simpler and more efficient alternative to existing treatments like TURP and ablative technologies. The company has received European Union CE approval for its first-generation device and is conducting clinical tests for its latest device. Butterfly has raised $9 million in funding, including investments from New Rhein Healthcare Investors and the Israel Innovation Authority. The company plans to open U.S. trials in early 2021 to seek FDA approval. Butterflys co-founders have backgrounds in medical devices and the company plans to expand its product offerings in the future.
Customers
growth-positive
Prostate implant co Butterfly Medical raises $7m
Israeli medical device company Butterfly Medical has raised $7 million in a Series B financing round led by New Rhein Healthcare Investors. The company is developing a novel implantable device to treat men suffering from enlarged prostates. Butterfly Medical has completed the enrollment of 49 patients in its clinical study and the results so far are positive. The funding will be used to conduct a pivotal US clinical trial and establish US headquarters. The device aims to provide a simpler and safer alternative to existing treatments for benign prostatic hyperplasia (BPH). BPH affects a significant portion of older men and can cause urinary tract obstruction and other symptoms. Butterfly Medical aims to offer a less invasive solution for patients.
InvestmentExpand
growth-positive
Butterfly Medical Ltd., a portfolio company of Alon Med-Tech Ventures, owned by Dr. Shimon Eckhouse, completes a $2M round of financing
Israeli medical device startup Butterfly Medical has completed a $2M round of financing led by Paul Merage, Kamran Siminou, Mori Arkin, Dan Suesskind, and several other private investors. The company has developed a non-surgical implant for the treatment of enlarged prostate symptoms. The implant is delivered to the prostatic urethra in a procedure that can be done at the physicians clinic, offering a simple and safe alternative to current treatments. A clinical trial in Israel has shown good clinical outcomes and demonstrated the procedures simplicity and safety. The investors participation is seen as a vote of confidence in the company and its technology. Butterfly Medical aims to provide a non-surgical treatment option for the millions of men affected by this condition.
InvestmentExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $9M |
| Last funding | $7M |
| Stage | B |
| Rounds | 2 |
| Investors | 6 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | butterfly-medical.com |
Locations
Yokneam, Israel
Photos & Videos
4 item(s)
